

A scientific & prospective meeting of the Marfans association

April 5th, 2024 - Espace Niemeyer

8h30-9h00	Welcome Coffee
9h00-9h15	Marfans 2035 - Vision and objectives of the Marfans patient organisation Stéphanie Delaunay, Chair of Marfans

Towards standardized research tools, coordinated at the European level:
Registries, biobanks, standardized protocols and animal models, new imaging techniques, artificial intelligence, etc.

9h15-9h40	An imaging biobank for new research projects Guillaume Jondeau
9h40-10h05	The high need for a rigorous multi-lab pre-clinical study protocol and platform to combat aortopathy in Marfan syndrome Bart Loeys
10h05-10h30	Genome-wide epistasis for cardiovascular severity in Marfan study design: patient organization driven research Lotte Van Den Heuvel
10h30-10h55	Medical course of patients with Marfan syndrome and related disorders Guillaume Jondeau
10h55-11h15	Coffee Break

Diagnostic biomarkers, patient stratification, multiparametric biomarkers for aneurysm monitoring and prediction of aortic dissection.

11h15-11h40	Enhancing aortic risk-stratification for effective research on medical therapies in syndromic HTAD patients Gisela Teixeira
11h40-12h05	Risk Biomarkers and Therapeutic Targets for Marfan and Loeys-Dietz Aortic Diseases Juan Miguel Redondo
12h05-12h30	Aortic wall microstructure and biomechanical properties in Marfan Syndrome Maxime Zimmermann
12h30-12h55	Dosage of elastin and its metabolites as a potential biomarker of aortic damage in Marfan disease Alexandre Guilhem
13h00-14h00	Lunch Break

14h00-14h25	Sex differences in clinical cardiovascular manifestations in Marfan syndrome Julie De Backer
14h25-14h50	What is the common process in distinct TAAs ? Using the « single cell » Carine Le Goff
14h50-15h15	Towards optimal treatment of Marfan syndrome Daan Bosshardt
15h15-15h30	Break

Novel therapeutic targets and strategies for Marfan Syndrome, Loeys-Dietz Syndrome and related syndromes.

15h30-15h55	Should we pursue with resveratrol in Marfan? Vivian De Waard
15h55-16h20	Multi-Target Pharmacological treatment strategy for translatable medicine from mouse models to human patients in Marfan Syndrome Gustavo Egea
16h20-16h55	Targeting Vascular Metabolism in Marfan Syndrome Jorge Oller Pedrosa PhD
16h55-17h20	ACTA2-related Hereditary Thoracic Aortic Aneurysms and Dissections (HTAAD) and Cellular Explorations (ACTA2 - FACE Project): Translational research of patients towards the α -actine structure to discover the pathophysiological mechanisms of the disease Laurence Bal-Theoleyre
17h20-17h45	Advancing Knowledge on the Musculoskeletal Impact of Marfan Syndrome: A 10-Year Program Thomas Edouard
17h45 -18h00	Wrap-up and future steps

Scan QR CODE for abstracts

